Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OligoG DPI in Cystic Fibrosis
NCT03822455Phase 2Terminated
- Sponsor
- AlgiPharma
- Start
- May 2019
- Primary completion
- Mar 2020
- Modality
- Oligosaccharide
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing OligoG DPI with Placebo DPI (2 arms). Primary endpoint: Absolute change in percent predicted FEV1 at 12 weeks. Started May 2019; status: terminated.
02
Drugs
OligoG
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03822455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822455.